Comparing the Digestion of Milk With Different Beta-casein Protein Content by Dairy Intolerant Persons

Dairy Intolerance Clinical Trial

Official title:

Comparing the Digestion of Milk With Different Beta-casein Protein Content by Dairy Intolerant Persons

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03713346
• Other study ID #: 1710019781
• Status: Completed
• Phase: N/A
• Start date: January 17, 2018
• Est. completion date: September 3, 2021

Study information

• Verified date: October 2021
• Source: Purdue University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Persons with dairy intolerance may experience cramps/abdominal pain, bloating, flatulence, acute diarrhea, or fecal urgency when they ingest excessive amounts of lactose. The intensity of these conditions can be mild or severe and likely depends on numerous variables including dose, transit time, intestinal residual lactase activity and microbiome potential to ferment lactose. Jersey cattle produce milk containing high levels of the A2 β-casein protein . There are claims that high A2 β-casein milk is more easily digested by people who are lactose maldigesters . We propose to conduct a double-blinded, randomized, controlled trial to determine if high A2 β-casein milk from Jersey cattle is actually better digested and tolerated by lactose maldigesters.

Description:

Persons with dairy intolerance may experience cramps/abdominal pain, bloating, flatulence, acute diarrhea, or fecal urgency when they ingest excessive amounts of lactose. The intensity of these conditions can be mild or severe and likely depends on numerous variables including dose, transit time, intestinal residual lactase activity and microbiome potential to ferment lactose. Jersey cattle produce milk containing high levels of the A2 β-casein protein . There are claims that high A2 β-casein milk is more easily digested by people who are lactose maldigesters . We propose to conduct a double-blinded, randomized, controlled trial to determine if high A2 β-casein milk from Jersey cattle is actually better digested and tolerated by lactose maldigesters.

This proposed protocol comparing the dairy intolerance symptoms from milks containing predominantly the A1 variant versus A2 variant will establish if high A2 milk is better digested and/or tolerated than high A1 milk.

Participants will be asked to consume four different commercially available milks in random order. The samples will be fed for breakfast separated by at least 10 days, after overnight fasts. The commercial milk treatments will include; high A1 β-casein milk (commercial milk), high A2 β-casein milk, Jersey cattle milk (which contains a mixture of A1 and A2 β-casein), and a lactose free milk control. Milk will be 2% fat content to control for transit. Each subject will be fed milk containing 0.5g lactose per kg body weight. There will be two arms in this study: dairy intolerant who are lactose maldigesters, and dairy intolerant who are lactose digesters.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 42
• Est. completion date: September 3, 2021
• Est. primary completion date: September 3, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Ability/desire to provide informed consent

2. Aged 18 to 65 years of age inclusive at screening

3. Current or recent history of intolerance to and avoidance of milk of at least one month duration (by self-report and self-reported symptoms).

4. Agrees to refrain from all other treatments and products used for lactose intolerance (e.g., Lactaid® Dietary Supplements) during study involvement

5. Willing to return for all study visits and complete all study related procedures, including fasting before and during the hydrogen breath tests

6. Qualifying Lactose Challenge Symptom Score:

(4 symptom categories with severity measured on from 0 to 5) as defined by one of the following:

1. At least one score of "moderately severe" or "severe" on a single symptom during the 6 hour HBT test;

2. A score of "moderate" or greater for a single symptom on at least two (2) time points during the 6 hour HBT test;

3. At least one "moderate" score or greater on each of two symptoms during the 6 hour HBT test 7. Hydrogen concentration of at least 20 parts per million greater than baseline at least 2 time points during the screening hydrogren breath test 8. Able to understand and provide written informed consent in English

Exclusion Criteria:

1. Allergic to milk

2. Currently pregnant

3. Currently lactating

4. Cigarette smoking or other use of tobacco or nicotine containing products within 3 months of screening

5. Diagnosed with any of the following disorders known to be associated with abnormal gastrointestinal motility such as; Gastroparesis, amyloidosis, neuromuscular diseases (including Parkinson's disease), collagen vascular diseases, alcoholism, uremia, malnutrition, or untreated hypothyroidism

6. History of surgery that alters the normal function of the gastrointestinal tract including, but not limited to: gastrointestinal bypass surgery, bariatric surgery, gastric banding, vagotomy, fundoplication, pyloroplasty [Note: history of uncomplicated abdominal surgeries such as removal of an appendix more than 12 months prior to screening will not be excluded]

7. Past or present : Organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, Celiac disease, chronic constipation, diverticulosis, inflammatory bowel disease (IBD), ulcerative colitis (UC), Crohn's disease (CD), small intestine bacterial overgrowth syndrome (SIBO), gastroparesis, gastro-esophageal reflux disease (GERD), Irritable Bowel Syndrome (IBS) or any other medical condition with symptoms that could confound collection of adverse events.

8. Active ulcers, or history of severe ulcers

9. Diabetes mellitus (type 1 and type 2)

10. Congestive Heart Failure (CHF)

11. Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C

12. BMI > 35 kg/m2

13. Recent bowel preparation for endoscopic or radiologic investigation within four weeks of screening (e.g., colonoscopy prep)

14. Use of concurrent therapy(ies) or other products (e.g., laxatives, stool softeners, Pepto Bismol®, Lactaid® Dietary Supplements) used for symptoms of lactose intolerance within 7 days of screening

15. Chronic antacid and/or PPI use

16. Recent use of systemic antibiotics defined as use within 30 days prior to screening

17. Recent high colonic enema, defined as use within 30 days prior to screening

18. Any concurrent disease or symptoms which may interfere with the assessment of the cardinal symptoms of lactose intolerance (i.e., gas, diarrhea, bloating, cramps, stomach pain)

19. History of ethanol (alcohol) and/or drug abuse in the past 12 months

20. Currently undergoing chemotherapy

21. Use of any investigational drug or participation in any investigational study within 30 days prior to screening

22. Prior enrollment in this study

23. Any other conditions/issues noted by the study staff and/or Principal Investigator that would impact participation and/or protocol compliance

-

Related Conditions & MeSH terms

• Dairy Intolerance

Intervention

Other:
• Lactose free milk
Single dose of lactose free milk
• Jersey milk
Single dose of jersey milk
• High A1 ß-casein milk
Single dose of high A1 ß-casein milk (commercial milk)
• High A2 ß-casein milk
Single dose of A2 ß-casein milk

Locations

Country	Name	City	State
United States	Purdue University	West Lafayette	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Purdue University

Country where clinical trial is conducted

United States, 

References & Publications (46)

Briet F, Pochart P, Marteau P, Flourie B, Arrigoni E, Rambaud JC. Improved clinical tolerance to chronic lactose ingestion in subjects with lactose intolerance: a placebo effect? Gut. 1997 Nov;41(5):632-5. — View Citation

Brown-Esters, O., Mc Namara, P., & Savaiano, D. (2012). Dietary and biological factors influencing lactose intolerance. International Dairy Journal, 22(2), 98-103.

Carroccio A, Montalto G, Cavera G, Notarbatolo A. Lactose intolerance and self-reported milk intolerance: relationship with lactose maldigestion and nutrient intake. Lactase Deficiency Study Group. J Am Coll Nutr. 1998 Dec;17(6):631-6. — View Citation

Dairy Farmer. (2011). Specialist A2 milk venture. Cengage Learning, Inc. 2.

Davies, D.T. & Law, A.J.R. (1980). The content and composition of creamery milks in south-west Scotland. J Dairy Res, 47, 80-90.

de Silva P, Rachman S. Human food aversions: nature and acquisition. Behav Res Ther. 1987;25(6):457-68. — View Citation

Dehkordi N, Rao DR, Warren AP, Chawan CB. Lactose malabsorption as influenced by chocolate milk, skim milk, sucrose, whole milk, and lactic cultures. J Am Diet Assoc. 1995 Apr;95(4):484-6. — View Citation

DOELL RG, KRETCHMER N. Studies of small intestine during development. I. Distribution and activity of beta-galactosidase. Biochim Biophys Acta. 1962 Aug 13;62:353-62. — View Citation

Gilliland SE, Kim HS. Effect of viable starter culture bacteria in yogurt on lactose utilization in humans. J Dairy Sci. 1984 Jan;67(1):1-6. — View Citation

Gustavsson F, Buitenhuis AJ, Johansson M, Bertelsen HP, Glantz M, Poulsen NA, Lindmark Månsson H, Stålhammar H, Larsen LB, Bendixen C, Paulsson M, Andrén A. Effects of breed and casein genetic variants on protein profile in milk from Swedish Red, Danish Holstein, and Danish Jersey cows. J Dairy Sci. 2014;97(6):3866-77. doi: 10.3168/jds.2013-7312. Epub 2014 Apr 3. — View Citation

Haverberg L, Kwon PH, Scrimshaw NS. Comparative tolerance of adolescents of differing ethic backgrounds to lactose-containing and lactose-free dairy drinks. I. Initial experience with a double-blind procedure. Am J Clin Nutr. 1980 Jan;33(1):17-21. — View Citation

Hayes, J. (2014). Farm Weekly. A2 milk drinkers may get less gut aches. Global Reference on the Environment, Energy, and Natural Resources.

He T, Priebe MG, Harmsen HJ, Stellaard F, Sun X, Welling GW, Vonk RJ. Colonic fermentation may play a role in lactose intolerance in humans. J Nutr. 2006 Jan;136(1):58-63. — View Citation

Hertzler SR, Savaiano DA. Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance. Am J Clin Nutr. 1996 Aug;64(2):232-6. — View Citation

Ho S, Woodford K, Kukuljan S, Pal S. Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: a blinded randomised cross-over pilot study. Eur J Clin Nutr. 2014 Sep;68(9):994-1000. doi: 10.1038/ejcn.2014.127. Epub 2014 Jul 2. — View Citation

Johnson AO, Semenya JG, Buchowski MS, Enwonwu CO, Scrimshaw NS. Adaptation of lactose maldigesters to continued milk intakes. Am J Clin Nutr. 1993 Dec;58(6):879-81. — View Citation

Johnson AO, Semenya JG, Buchowski MS, Enwonwu CO, Scrimshaw NS. Correlation of lactose maldigestion, lactose intolerance, and milk intolerance. Am J Clin Nutr. 1993 Mar;57(3):399-401. — View Citation

Kolars JC, Levitt MD, Aouji M, Savaiano DA. Yogurt--an autodigesting source of lactose. N Engl J Med. 1984 Jan 5;310(1):1-3. — View Citation

Kretchmer N. Lactose and lactase--a historical perspective. Gastroenterology. 1971 Dec;61(6):805-13. Review. — View Citation

Kretchmer N. On the homology between human development and pediatrics. Pediatr Res. 1968 Jul;2(4):283-6. — View Citation

Lee CM, Hardy CM. Cocoa feeding and human lactose intolerance. Am J Clin Nutr. 1989 May;49(5):840-4. — View Citation

Leichter J. Comparison of whole milk and skim milk with aqueous lactose solution in lactose tolerance testing. Am J Clin Nutr. 1973 Apr;26(4):393-6. — View Citation

Lerebours E, N'Djitoyap Ndam C, Lavoine A, Hellot MF, Antoine JM, Colin R. Yogurt and fermented-then-pasteurized milk: effects of short-term and long-term ingestion on lactose absorption and mucosal lactase activity in lactase-deficient subjects. Am J Clin Nutr. 1989 May;49(5):823-7. — View Citation

Logue AW, Ophir I, Strauss KE. The acquisition of taste aversions in humans. Behav Res Ther. 1981;19(4):319-33. — View Citation

Martini MC, Savaiano DA. Reduced intolerance symptoms from lactose consumed during a meal. Am J Clin Nutr. 1988 Jan;47(1):57-60. — View Citation

Moore BJ. Dairy Foods: Are They Politically Correct? Nutr Today. 2003 May-Jun;38(3):82-90. — View Citation

Newcomer AD, McGill DB, Thomas PJ, Hofmann AF. Tolerance to lactose among lactase-deficient American Indians. Gastroenterology. 1978 Jan;74(1):44-6. — View Citation

Ng-Kwai-Hang KF & Grosclaude F. (2003). Genetic polymorphism of milk proteins. Advanced Dairy Chemistry, 1, 739-816.

Perets, T., Shporn, E., Bareli, Y., Kelner, Y., Levy, S., Aizic, S., Pakanaev, L., Niv, Y., & Dickman, R. (2013). Clinical Accuracy and Usefulness of the Lactose Intolerance Quick Test for the Diagnosis of Lactose Malabsorption. Gastroenterology, 144(5), S473

Rask Pedersen E, Jensen BH, Jensen HJ, Keldsbo IL, Hylander Møller E, Nørby Rasmussen S. Lactose malabsorption and tolerance of lactose-hydrolyzed milk. A double-blind controlled crossover study. Scand J Gastroenterol. 1982 Oct;17(7):861-4. — View Citation

Reasoner J, Maculan TP, Rand AG, Thayer WR Jr. Clinical studies with low-lactose milk. Am J Clin Nutr. 1981 Jan;34(1):54-60. — View Citation

Rosensweig NS. Adult human milk intolerance and intestinal lactase deficiency. A review. J Dairy Sci. 1969 May;52(5):585-7. Review. — View Citation

Savaiano DA, AbouElAnouar A, Smith DE, Levitt MD. Lactose malabsorption from yogurt, pasteurized yogurt, sweet acidophilus milk, and cultured milk in lactase-deficient individuals. Am J Clin Nutr. 1984 Dec;40(6):1219-23. — View Citation

Savaiano DA, Levitt MD. Milk intolerance and microbe-containing dairy foods. J Dairy Sci. 1987 Feb;70(2):397-406. Review. — View Citation

Savaiano, D., Hertzler, S., Jackson, A. J., & Suarez, F. L. (2001). Nutrient considerations in lactose intolerance. In A. M. Coulston, C. L. Rock, & E. R. Monsen (Eds.), Nutrition in the prevention and treatment of disease San Diego, CA, USA: Academic Press. 563-575

Scrimshaw NS, Murray E. [Lactose tolerance and milk consumption: myths and realities]. Arch Latinoam Nutr. 1988 Sep;38(3):543-67. Review. Spanish. — View Citation

Shermak MA, Saavedra JM, Jackson TL, Huang SS, Bayless TM, Perman JA. Effect of yogurt on symptoms and kinetics of hydrogen production in lactose-malabsorbing children. Am J Clin Nutr. 1995 Nov;62(5):1003-6. — View Citation

Simoons FJ. The geographic hypothesis and lactose malabsorption. A weighing of the evidence. Am J Dig Dis. 1978 Nov;23(11):963-80. Review. — View Citation

Solomons NW, Guerrero AM, Torun B. Dietary manipulation of postprandial colonic lactose fermentation: II. Addition of exogenous, microbial beta-galactosidases at mealtime. Am J Clin Nutr. 1985 Feb;41(2):209-21. — View Citation

Suarez FL, Adshead J, Furne JK, Levitt MD. Lactose maldigestion is not an impediment to the intake of 1500 mg calcium daily as dairy products. Am J Clin Nutr. 1998 Nov;68(5):1118-22. — View Citation

Suarez FL, Savaiano D, Arbisi P, Levitt MD. Tolerance to the daily ingestion of two cups of milk by individuals claiming lactose intolerance. Am J Clin Nutr. 1997 May;65(5):1502-6. — View Citation

Suarez FL, Savaiano DA, Levitt MD. Review article: the treatment of lactose intolerance. Aliment Pharmacol Ther. 1995 Dec;9(6):589-97. Review. — View Citation

Suchy FJ, Brannon PM, Carpenter TO, Fernandez JR, Gilsanz V, Gould JB, Hall K, Hui SL, Lupton J, Mennella J, Miller NJ, Osganian SK, Sellmeyer DE, Wolf MA. National Institutes of Health Consensus Development Conference: lactose intolerance and health. Ann Intern Med. 2010 Jun 15;152(12):792-6. doi: 10.7326/0003-4819-152-12-201006150-00248. Epub 2010 Apr 19. — View Citation

Swagerty DL Jr, Walling AD, Klein RM. Lactose intolerance. Am Fam Physician. 2002 May 1;65(9):1845-50. Review. Erratum in: Am Fam Physician. 2003 Mar 15;67(6):1195. — View Citation

Truswell AS. The A2 milk case: a critical review. Eur J Clin Nutr. 2005 May;59(5):623-31. Review. — View Citation

Welsh JD, Hall WH. Gastric emptying of lactose and milk in subjects with lactose malabsorption. Am J Dig Dis. 1977 Dec;22(12):1060-3. — View Citation

* Note: There are 46 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differences in AUC ?H2 concentrations	Differences in AUC ?H2 concentrations (primary outcomes) among milk phases is examined by repeated-measures analysis of variance (ANOVA)	Within the 6 hours following the milk challenge
Secondary	Differences within each of the symptom categories	Repeated-measures ANOVA is also used to test for differences within each of the symptom categories (secondary outcomes) after transforming to correct for nonstationary variance. For both the H2 concentrations and symptom levels, to be able to detect differences between every single treatment, pairwise differences are examined using least significant difference (LSD).	Within the 6 hours following the milk challenge